Surgery of locally advanced and metastatic kidney cancer after tyrosine kinase inhibitors therapy: single institute experience

Abstract

Purpose:

Renal cell carcinoma (RCC) is the most common tumor of the kidney. Considering the TNM classification of 2009, locally advanced and metastatic diseases are included in the groups stage III and IV. The surgical treatment of these tumors could be divided into 3 categories: (1) curative (nephrectomy and/or metastasectomy), (2) cytoreductive, and (3) palliative. Targeted agents showed impressive antitumor efficacy and prolongation of progression-free survival. The integration between target therapy and surgery in patients with locally advanced or metastatic RCC has sometimes facilitated surgery. We aimed to evaluate patients’ response to tyrosine kinase inhibitor (TKI) therapy and the feasibility of surgery after that and to observe complications related to surgery.

Methods:

From February 2007 to September 2014 in the Istituto Tumori of Milan, IRCCS, we selected patients with locally advanced or metastatic diseases, treated with target therapy before surgery (which comprised nephrectomy or partial nephrectomy, cytoreductive surgery, and metastasectomy) and cryoablation.

Results:

We selected 33 patients who underwent surgery after TKI therapy. As for response to TKIs, 20 patients (60%) had stable disease, 9 patients (28%) had a partial response, and 4 patients (12%) had progressive disease. A total of 17 patients (51%) presented complications directly or indirectly related to surgery and most of those were classified as grade II Clavien-Dindo score.

Conclusions:

The association between TKI and surgery seems to have no contraindications. Our dataset provides an example of how surgery after TKI is possible in locally advanced metastatic tumor and does not have an excessive rate of postoperative complications.

Keywords

Locally advanced and metastatic kidney cancer Renal cell carcinoma Surgery of RCC Tyrosine kinase inhibitor

Get full access to this article

View all access options for this article.

References

Chen

Uzzo

. Optimal management of localized renal cell carcinoma: surgery, ablation, or active surveillance. J Natl Compr Canc Netw. 2009;7(6):635-642, quiz 643.

Russo

. The role of surgery in the management of early-stage renal cancer. Hematol Oncol Clin North Am. 2011;25(4):737-752.

Pizzocaro

Piva

Colavita

et al . Interferon adjuvant to radical nephrectomy in Robson stages II and III renal cell carcinoma: a multicentric randomized study. J Clin Oncol. 2001; 19(2):425-431.

Messing

Manola

Wilding

et al ; Eastern Cooperative Oncology Group/Intergroup trial. Phase III study of interferon alfa-NL as adjuvant treatment for resectable renal cell carcinoma: an Eastern Cooperative Oncology Group/Intergroup trial. J Clin Oncol. 2003;21(7):1214-1222.

Clark

Atkins

Urba

et al . Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trial. J Clin Oncol. 2003; 21(16):3133-3140.

Passalacqua

Buzio

Buti

et al . Adjuvant low5dose interleukin-2 (IL2) plus interferone-alpha (IFN-α) in operable renal cell cancer (RCC). A phase III, randomized, multicenter, independent trial of the Italian Oncology Group for Clinical Research (GOIRC). 2007 ASCO Annual Meeting:LBA5028.

Motzer

Michaelson

Redman

et al . Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol. 2006;24(1):16-24.

Ratain

Eisen

Stadler

et al . Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2006; 24(16):2505-2512.

Motzer

Hutson

Tomczak

et al . Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356(2):115-124.

10.

Silberstein

Millard

Mehrazin

et al . Feasibility and efficacy of neoadjuvant sunitinib before nephron-sparing surgery. BJU Int. 2010;106(9):1270-1276.

11.

Ansari

Doherty

McCafferty

Wallace

Deshmukh

Porfiri

. Neoadjuvant sunitinib facilitates nephron-sparing surgery and avoids long-term dialysis in a patient with metachronous contralateral renal cell carcinoma. Clin Genitourin Cancer. 2009;7(2):E39-E41.

12.

ClinicalTrials.gov. Clinical Trial to Assess the Importance of Nephrectomy (CARMENA). http://clinicaltrials.gov/ct2/show/NCT00930033.

13.

EORTC SURTIME 30073- GUCG.

14.

Eisenhauer

Therasse

Bogaerts

et al . New response evaluation criteria in solid tumors: revised RECIST guidelines (version1.1). Eur J Cancer. 2009;45(2):228-247.

15.

Clavien

Barkun

de Oliveira

et al . The Clavien-Dindo classification of surgical complications: five-year experience. Ann Surg. 2009;250(2):187-196.

16.

Lane

Derweesh

Kim

HLO

et al . Presurgical sunitinib reduces tumor size and may facilitate partial nephrectomy in patients with renal cell carcinoma. Urol Oncol. 2015;33(3):112.e15-112.e21.

17.

Bex

van der Veldt

Blank

et al . Neoadjuvant sunitinib for surgically complex advanced renal cell cancer of doubtful resectability: initial experience with downsizing to reconsider cytoreductive surgery. World J Urol. 2009;27(4):533-539.

18.

Cowey

Amin

Pruthi

et al . Neoadjuvant clinical trial with sorafenib for patients with stage II or higher renal cell carcinoma. J Clin Oncol. 2010;28(9):1502-1507.

19.

Harshman

Allen

Srinivas

Gill

Chung

. Surgical outcomes and complications associated with presurgical tyrosine kinase inhibition for advanced renal cell carcinoma (RCC). Urol Oncol. 2013;31(3):379-385.

20.

Tsuzuki

Sassa

Shimoyama

et al . Tyrosine kinase inhibitor-induced vasculopathy in clear cell renal cell carcinoma: an unrecognized antitumour mechanism. Histopathology. 2014; 64(4):484-493.

21.

Bayer Pharmaceutical Co., Sorafenib package insert, 2009.

22.

Pfizer, Sunitinib maleate package insert 2010.

23.

Blom

van Poppel

Maréchal

et al ; EORTC Genitourinary Tract Cancer Group. Radical nephrectomy with and without lymph-node dissection: final results of European Organization for Research and Treatment of Cancer (EORTC) randomized phase 3 trial 30881. Eur Urol. 2009;55(1):28-34.

24.

Bekema

MacLennan

Imamura

et al . Systematic review of adrenalectomy and lymph node dissection in locally advanced renal cell carcinoma. Eur Urol. 2013;64(5):799-810.

25.

Capitanio

Becker

Blute

et al . Lymph node dissection in renal cell carcinoma. Eur Urol. 2011;60(6):1212-1220.

26.

Capitanio

Suardi

Matloob

et al . Extent of lymph node dissection at nephrectomy affects cancer-specific survival and metastatic progression in specific sub-categories of patients with renal cell carcinoma (RCC). BJU Int. 2014;114(2):210-215.